Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atuliflapon versus placebo in adults with moderate to severe uncontrolled asthma
NL-OMON59602Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atuliflapon in asthma, sponsored by AstraZeneca. Primary endpoint: Time to first CompEx Asthma event. Started Apr 2023; status: completed.
02
Drugs
atuliflapon
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON59602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59602.